Entera Bio (ENTX) Stock Overview
A clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
+ 1 more risk
ENTX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Entera Bio Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.24 |
| 52 Week High | US$3.22 |
| 52 Week Low | US$0.91 |
| Beta | 1.55 |
| 1 Month Change | 10.71% |
| 3 Month Change | -21.52% |
| 1 Year Change | -36.41% |
| 3 Year Change | 57.78% |
| 5 Year Change | -61.61% |
| Change since IPO | -80.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| ENTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.8% | 2.4% | 1.1% |
| 1Y | -36.4% | 34.6% | 28.7% |
Return vs Industry: ENTX underperformed the US Biotechs industry which returned 34.6% over the past year.
Return vs Market: ENTX underperformed the US Market which returned 28.7% over the past year.
Price Volatility
| ENTX volatility | |
|---|---|
| ENTX Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ENTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ENTX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 21 | Miranda Toledano | enterabio.com |
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption.
Entera Bio Ltd. Fundamentals Summary
| ENTX fundamental statistics | |
|---|---|
| Market cap | US$61.04m |
| Earnings (TTM) | -US$12.38m |
| Revenue (TTM) | n/a |
Is ENTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$12.38m |
| Earnings | -US$12.38m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ENTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/25 07:51 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Entera Bio Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| null null | CG Capital |
| Raghuram Selvaraju | H.C. Wainwright & Co. |